Gliatilin, 400 mg capsules 14 pcs

Acquired dementia, Aggressiveness and conflict, Attention and memory disorders, Stroke sequelae, Headache, Mental disorders, Alzheimer’s disease

• Acute period of trauma with predominantly brain stem level lesions (impaired consciousness, coma, focal hemispheric symptoms, symptoms of brain stem damageAcute period of a traumatic brain injury with predominantly trunk level lesions (impaired consciousness, coma, focal hemispheric symptoms, symptoms of brainstem lesions);
• ischemic (acute and recovery period) and hemorrhagic stroke (recovery period);
• degenerative and involutionary psychoorganic syndromes and consequences of cerebrovascular failure, such as primary and secondary disorders of mnemonic functions, characterized by memory disturbances, confusion, disorientation, decreased motivation, initiative, ability to concentrate;
• changes in the emotional and behavioral sphere: emotional lability, increased irritability, decreased interest, senile pseudo-melancholy;
• multiple dementia.

.

Indications

acute period of TBI with a predominantly brain stem level of damage (impaired consciousness, coma, focal hemispheric symptoms, symptoms of brain stem damage);
ischemic (acute and recovery period) and hemorrhagic stroke (recovery period);
degenerative and involutional psychoorganic syndromes and consequences of cerebrovascular insufficiency, such as primary and secondary disorders of mnestic functions, characterized by memory impairment, confusion, disorientation, decreased motivation, initiative, and ability to concentrate;
changes in the emotional and behavioral sphere: emotional lability, increased irritability, decreased interest, senile pseudomelancholy;
multi-infarct dementia.

Special instructions

Experimental studies have not established the mutagenic effect of the drug.

– Impact on the ability to drive vehicles and operate machinery Gliatilin does not affect the patient’s ability to engage in potentially hazardous activities.

Active ingredient

Choline alphoscerate

Composition

Active ingredient:

choline alfoscerate 400 mg;

Excipients:

purified water;

glycerol;

Capsule shell:

gelatin;

esitol;

sorbitans;

sodium ethyl parahydroxybenzoate;

sodium propyl parahydroxybenzoate;

titanium dioxide (E171);

iron (III) metahydroxide (E172)

Contraindications

Hypersensitivity to the components of the drug.

Side Effects

Nausea (as a consequence of dopaminergic activation), in this case the dose of the drug should be reduced.

Allergic reactions are possible.

Interaction

Drug interactions with Gliatilin have not been established.

Overdose

Symptoms: nausea.

If this symptom appears, it is recommended to reduce the dose of the drug.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

3 years

Manufacturer

Catalent Italy S.P.A., Italy